Haeseong Park, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (857) 215-1230
Fax: (617) 632-5370


Haeseong_Park@dfci.harvard.edu

Haeseong Park, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Associate Physician , Gastrointestinal oncology , Dana-Farber Cancer Institute
  • Associate Physician , medical oncology , Brigham & Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a GI medical oncologist and clinical investigator with clinical focus in gastroesophageal cancers. My goal is to provide patients suffering from advanced cancers with novel, effective therapeutic options that will extend survival and improve quality of life. My research focus is in early phase clinical trials for which I completed an advanced fellowship in Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. I have then served as the Co-Director of Developmental Therapeutics Program at Siteman Cancer Center/ Washington University School of Medicine while serving as the AO-PI of the UM1 grant to support Experimental Therapeutics Clinical Trial Network (ETCTN) under Yale LAO. I have served on the institutional Protocol Review Monitoring Committee for scientific prioritization of clinical trials and the Data Safety Monitoring Board. I am currently serving as a member of NCI Esophagogastric Task Force.

I have subsequently joined Dana Farber Cancer Institute (DFCI) as a member of Gastrointestinal Cancer Center and Center for Cancer Therapeutic Innovations. In my current position, I lead the early phase, translational clinical trial development efforts with focus in gastrointestinal cancers. In addition, I actively participate in development of gastroesophageal cancer clinical research program in both early and late phases. During and since training I have been actively involved in developing, enrolling for, and analyzing several clinical trials. These include both ETCTN and National Clinical Trials Network (NCTN)-supported trials or industry-sponsored as well as institutionally funded clinical trials.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Ibrahim D, Simó C, Brown EL, Shmuel S, Panikar SS, Benton A, DeWeerd R, Dehdashti F, Park H, Pereira PMR. PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET. 2024; 15:1405485. PubMed
  • Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20:167-192. PubMed
  • Trikalinos NA, Robinson CG, Park H. Selection of Neoadjuvant Treatment Arms in Trials of Patients With Squamous Cell Cancer of the Esophagus. JAMA Surg 2022; 157:83-84. PubMed
  • Grierson PM, Park H. Capitalizing on Success of Systemic Therapy to Improve Outcomes of Intermediate-Stage HCC. JCO Oncol Pract 2022; 18:43-44. PubMed
  • Kim H, Pedersen K, Olsen JR, Mutch MG, Chin RI, Glasgow SC, Wise PE, Silviera ML, Tan BR, Wang-Gillam A, Lim KH, Suresh R, Amin M, Huang Y, Henke LE, Park H, Ciorba MA, Badiyan S, Parikh PJ, Roach MC, Hunt SR. Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial. Clin Colorectal Cancer 2021; 20:e185-e193. PubMed
  • Camidge DR, Park H, Smoyer KE, Jacobs I, Lee LJ, Askerova Z, McGinnis J, Zakharia Y. Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials. Future Oncol 2021; 17:3271-3280. PubMed